A radically redesigned viral vector may improve the delivery of therapeutic genes to patients with sickle-cell disease. According to tests in animal models, the new vector is up to ten times more efficient at incorporating corrective genes into bone marrow stem cells than conventional vectors, and it has a carrying capacity that is up to six times higher. (source: genengniews.com)
(No Ratings Yet)
Loading...
